⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PVLA News
Palvella Therapeutics, Inc. Common Stock
ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors
prnewswire.com
PVLA
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
globenewswire.com
PVLA
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
globenewswire.com
PVLA
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
globenewswire.com
PVLA
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA